RxDoctor Payments Data

Youssef Wassef

Pain Medicine · Gainesville, FLNPI 1205936770

Payments from drug & device makers

$4,953in general payments, 2019–2025

Across 197 payments — averaging $25.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Nevro Corp.$2K
  • Pfizer$431
  • Boston Scientific$328
  • Indivior Inc.$289
  • Braeburn Inc.$237
  • AbbVie$218
  • plus $2K from 29 others

What the payments were for

  • Travel & lodging$2255%
  • Food & beverage$4,68395%
  • Education$451%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,953 in reported general payments places this provider in the 65th percentile of 596 pain medicine providers in Florida.

See all pain medicine providers in Florida

Medicare billing

Part B allowed, 2024
$164,561
Medicare patients
118
Services billed
2,516

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SublocadeBuprenorphine42$92,357
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl313$45,017
BrixadiBuprenorphine19$32,347
Xtampza ErOxycodone Myristate29$18,354
QuliptaAtogepant13$16,360
Buprenorphine76$14,708
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen359$10,416
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen278$9,089
Diclofenac Epolamine12$7,690
Varenicline Tartrate38$6,751
Oxycodone Hcl345$5,974
Gabapentin227$4,636
ButransBuprenorphine11$4,516
Megestrol Acetate44$2,974
Duloxetine Hcl172$2,640

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Indivior Inc.Sublocade$289$92,35742 claims
Braeburn Inc.Brixadi$237$32,34719 claims
AbbVieQulipta$218$16,36013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 596 pain medicine providers in Florida.

Other pain medicine in Gainesville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →